VERADIGM INC (MDRX)
(Delayed Data from OTC)
$4.75 USD
0.00 (0.00%)
Updated Aug 6, 2025 03:49 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MDRX 4.75 0.00(0.00%)
Will MDRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDRX
GE HealthCare Acquires Intelligent Ultrasound's Clinical AI Business
MDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MDRX
U.S. health authorities, tech firms to discuss data sharing plan: Bloomberg News
Veradigm (MDRX) Receives a Buy from TD Cowen
Veradigm Provides 2025 Financial & Business Update | MDRX Stock News
Veradigm Inc (MDRX) Reports Q1 2025 Revenue Between $145M and $147M, Highlights $30M in New Deals
Veradigm Secures $100M Credit Agreement for Strategic Growth